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Abstract 
Four arene osmium complexes were prepared containing derivatives of ethacrynic acid, a potent 
inhibitor of glutathione S-transferases, either by direct coordination or via N- or P-donor ligands. The 
complexes were characterized by spectroscopic and analytical methods and, for Os(η6-p-
cymene)(acetylacetonato)(2-(2,3-dichloro-4-(2-ethylenebutanoyl)phenoxy) acetato) and Os(η6-p-
cymene)Cl2(2-(2-(2,3-dichloro-4-(2-methylenebutanoyl)phenoxy)acetoxy)ethyl nicotinato), by single-
crystal X-ray diffraction. The cytotoxicity of the complexes towards the human ovarian cancer cells 
and non-tumorous human embryonic kidney cells was investigated, and two of the complexes, for 
which ruthenium analogues are known, helped to delineate the influence of the metal ion. Inhibition 
studies of intracellular glutathione S-transferases (GSTs - detoxification enzymes implicated in drug 
resistance) indicate that the observed cytotoxicity of the complexes involves GST inhibition, as well as 
other targets following dissociation of the ethacrynic acid group from the osmium(II) ion. 
 
Keywords: bioorganometallic chemistry, bioinorganic chemistry, metal-based drugs, arene osmium 
complexes, ethacrynic acid. 
 
Introduction 
Arene ruthenium(II) complexes have been intensively investigated as possible anticancer agents,1 and 
especially those complexes containing 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (RAPTA 
complexes) and ethylene-1,2-diamine as ligands show promising antitumor properties.2 On account of 
the proximity of ruthenium and osmium in the same group of the periodic table, a variety of osmium(II) 
derivatives have been considered as a natural extension of this research.3 In particular, arene osmium 
complexes usually exhibit slower rates for ligands exchange than the ruthenium analogues, a desirable 
property providing increased drug stability under physiological conditions.4 
 
One of the common approaches aimed at improving the efficacy of metal drugs consists of 
incorporating an organic fragment with a complementary biological function.5 This strategy has already 
been applied also to various anticancer arene ruthenium(II) and osmium(II) complexes, which have 
been functionalized with biologically active moieties such as 3-hydroxyflavones,6 lapachol,7 
paullones,8 and lonidamine.9 
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It has previously been shown that ethacrynic acid, originally developed as an inhibitor of glutathione S-
transferases (GSTs, a family of cytosolic detoxification enzymes associated with drug resistance), 
potentiates the cytotoxic effect of several chemotherapeutic agents, including cisplatin.10 Consequently, 
in an attempt to overcome drug resistance, ethacrynic acid has been tethered to the ruthenium(II)-arene 
framework via two distinct synthetic approaches, i.e. the modification of the arene ligand 11 and the 
introduction via an appropriate monodentate ligand. In this respect, ethacrynic acid-functionalized 
imidazole,12 pyridine and triphenylphosphine-type 13 ligands have been used (Figure 1). Also 
ruthenium(III), platinum(II) and platinum(IV) complexes with ethacrynic acid-derived appendages 
have been prepared and tested as anticancer drugs.14  
 
Figure 1. Structures of ethacrynic acid and of arene ruthenium(II) complexes containing ethacrynic acid-modified 
ligands. 
 
All the ruthenium and platinum complexes modified with ethacrynic acid manifest increased ability to 
inactivate GSTs and induce apoptosis, even in cisplatin resistant cell lines.15 To the best of our 
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knowledge, the inclusion of ethacrynic acid in osmium complexes has not been reported heretofore. In 
the present paper, the synthesis, characterization and biological activity of a series of four osmium 
complexes containing ethacrynic acid-modified ligands (including two complexes for which Ru-
analogues are known) are described. 
 
Results and discussion 
The direct reaction of the bis-acetylacetonato complex Os(η6-p-cymene)(κ(C)-acac)(κ(O,O')-acac)16 
with ethacrynic acid proceeded at room temperature to give complex 1, which was isolated as a bright 
yellow solid in 75% yield (Scheme 1). 
 
 
 
Scheme 1. Synthesis of osmium(II)-p-cymene ethacrynato complex 1. 
 
The ethacrynic acid-functionalized ligands 2-((4-(diphenylphosphanyl)benzyl)oxy)ethyl-2-(2,3-
dichloro-4-(2-methylenebutanoyl)phenoxy)acetato (LP)13 and 2-(2-(2,3-dichloro-4-(2-
methylenebutanoyl)phenoxy)acetoxy)ethyl-nicotinato (LN),13 and 1,3,5-triaza-7-
phosphatricyclo[3.3.1.1]decane (PTA)17 were prepared according to literature procedures. Then the 
ligands were allowed to react with the dimer [Os(η6-p-cymene)Cl2]2, to give the corresponding 
mononuclear complexes 2 and 3 in 90% and 75% yield, respectively, and [Os(η6-p-
cymene)Cl2(PTA)]
18 (Scheme 2). [Os(η6-p-cymene)Cl2(PTA)]was further treated with LN, in the 
presence of silver tetrafluoroborate, to afford 4 in an overall yield of 81%. 
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Scheme 2. Synthesis of the complexes 2 – 4 containing ethacrynic acid-modified ligands. 
 
Complexes 1 - 4 are air-stable in the solid state and when dissolved in chlorinated solvents. Complex 4 
is a racemate, due to the presence of a stereogenic osmium center. Complexes 1 - 3 in CH2Cl2 exhibit 
molar conductance values in the range 0.12 − 0.41 S·cm2·mol–1, while the value found for 4 is 9.32 
S·cm2·mol–1, in agreement with the neutral character of 1 - 3 and the ionic character of 4. The IR 
spectra of 1 - 4 (solid state) display a series of absorptions in the range 1759-1518 cm-1, attributable to 
the stretching vibrations of different carbonyl moieties. The NMR spectra of 1-4 (in CD2Cl2) contain 
single sets of resonances. The carbonyl carbon atom of the ethacrynato moiety in 1 exhibits a resonance 
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at 172.5 ppm in the 13C NMR spectrum, i.e. at comparable frequency than that in ethacrynic acid itself 
(172.8 ppm). The 1H and 13C NMR spectra of 2 - 3 display the resonances due to the LP and LN 
ligands close in value to those observed for the same ligands coordinated in analogous ruthenium 
complexes.13 As a consequence of the formal substitution of a chloride with PTA on going from the 
neutral complex 3 to the cationic 4, the resonances of some pyridyl nuclei undergo significant shift to 
higher frequency (∆δC20-H = 0.27 ppm in the 
1H spectra; ∆δC19 = 3.1 ppm, ∆δC17 = 1.6 ppm and ∆δC20 = 
2.6 ppm in the 13C spectra; see Chart 4). The 31P NMR resonance in 2 (at −12.1 ppm) appears at lower 
frequency respect to the free ligand, LP (−4.9 ppm),13 whereas the 31P NMR resonance due to the PTA 
ligand in 4 (−77.4 ppm) resembles the values previously reported for related arene osmium(II) 
complexes.19 The expected structures of 1 - 4 were further corroborated by mass spectrometry and 
elemental analysis (see Experimental).  
 
Crystals of 1 and 3 suitable for X-ray diffraction analysis were obtained from CH2Cl2/pentane and 
CH2Cl2/hexane mixtures, respectively. A small amount of hydroquinone was added in order to 
facilitate the crystallization of 3.20 The structures of 1 and 3 are shown, respectively, in Figures 2 and 3, 
while selected bond distances and angles are given in Tables 1 and 2. Complexes 1 and 3 adopt the 
characteristic three-leg piano-stool geometry, comprising the p-cymene "seat".3b,7,18,21 The three "leg" 
positions are occupied by the bidentate acac ligand [O(5)-Os-O(6) bite angle 88.14(9)º] and the 
monodentate carboxylate [O(1)-Os-O(5) and O(1)-Os-O(6) angles are 80.59(10)º and 77.35(10)º, 
respectively] in 1, and by LN and two chlorides in 3 [N(1)-Os-Cl(1), N(1)-Os-Cl(2), and Cl(1)-Os-
Cl(2) angles measure 82.20(10)º, 86.62(10)º, and 85.08(4)º, respectively]. The bonding parameters of 
the EA units are not significantly different from those found in other reported structures.10a,12,13,22 
Compound 1 represents the first example of crystallographically characterized osmium p-cymene 
complex with a monodentate carboxylate ligand: the Os-O(1) bond length [2.081(3) Å] is reminiscent 
of the situation found in other Os(II)-monodentate carboxylate systems.23 The Os-O(5) and Os-O(6) 
bond lengths [2.072(2) and 2.081(2) Å, respectively] in 1 resemble those previously reported for other 
Os(II)-acac complexes.21b,24  
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Figure 2. Molecular structure of 1. Displacement ellipsoids are at the 50% probability level. Hydrogen atoms are 
omitted for clarity. 
 
Table 1. Selected bond distances (Å) and angles (°) for  1. 
Os-C(23) 2.147(3) Os-C(24) 2.179(4) 
Os-C(25) 2.195(4) Os-C(27) 2.176(3) 
Os-C(28) 2.150(3) Os-C(19) 2.188(3) 
Os-O(5) 2.072(2) Os-O(6) 2.081(2) 
Os-O(1) 2.081(3) O(1)-C(1) 1.286(4) 
O(2)-C(1) 1.224(4) C(1)-C(2) 1.521(5) 
O(5)-Os-O(6) 88.14(9) O(5)-Os-O(1) 80.59(10) 
O(1)-Os-O(6) 77.35(10) Os-O(1)-C(1) 126.5(2) 
O(1)-C(1)-O(2) 128.1(3) O(1)-C(1)-C(2) 114.0(3) 
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Figure 3. Molecular structure of 3. Displacement ellipsoids are at the 50% probability level. Hydrogen atoms are 
omitted for clarity. 
Table 2. Selected bond distances (Å) and angles (°) for 3. 
Os-C(22) 2.193(4) Os-C(26) 2.162(4) 
Os-C(27) 2.182(5) Os-C(28) 2.192(4) 
Os-C(30) 2.180(5) Os-C(31) 2.149(4) 
Os-Cl(1) 2.4231(11) Os-Cl(2) 2.4155(11) 
Os-N(1) 2.119(3) N(1)-Os-Cl(2) 86.62(10) 
N(1)-Os-Cl(1) 82.20(10) Cl(2))-Os-Cl(1) 85.08(4) 
 
NMR and UV-Vis spectroscopy, and conductivity measurements were used to assess the stability of the 
complexes 1 - 4 in dmso/water solutions at 37 °C as a function of time. Parallel NMR and UV-Vis 
analyses were carried out also on 1 - 4 in 0.1 M sodium chloride dmso/water solutions (this chloride 
concentration being similar to that present in blood). The compounds identified from these studies are 
depicted in Scheme 3.  
A complicated mixture of compounds form from 1 in dmso/water, and two sets of resonances have 
been tentatively assigned to 1a and 1b; the ethacrynato moiety behaves as a leaving group, and the 
NaCl environment accelerates this dissociation. EA-CO2K was prepared from EA-CO2H/KN(SiMe3)2 
and characterized in order to identify EA-CO2
− in the studied solutions (see Experimental).  
Conductivity data suggest that 2 - 4 undergo rapid solvolysis in dmso/water, presumably via the release 
of a chloride ligand. According to NMR and UV-Vis spectroscopy, this phenomenon does not appear 
to be inhibited in the presence of NaCl 0.1 M.  
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It should be noted that the ligands LP and LN in 2 and 3 are less prone to dissociation than that 
previously observed for the analogous ruthenium complexes.13 Indeed, LP in 2 is substantially inert 
towards dissociation (5% released after 72 hours in dmso/water and 12% released after 72 hours in the 
chloride containing solution). Spectroscopic and conductivity studies indicate that only minor amounts 
of 3 and 4 remain unchanged in the dmso/water and dmso/water/NaCl solutions for 62-72 hours, and 
that the LN ligand and chloride ligand compete for the exchange with the solvent in both cases. 
Interestingly, the dissociation of the LN ligand from 3 and to a greater extent from 4 is partially 
suppressed in the respective NaCl solutions.  
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Scheme 3. Compounds detected in dmso/H2O and dmso/H2O/NaCl solutions of 1-4 maintained at 37 °C; % 
values are based on 1H NMR spectroscopy and refer to the identified compounds only. a Not soluble under the 
experimental conditions. 
  
Cytotoxicity studies 
The ability of the complexes 1 – 4 to inhibit cell growth was evaluated against the cisplatin sensitive 
A2780 and the cisplatin resistant A2780cisR human ovarian carcinoma cell lines and non-tumoral 
immortalized human embryonic kidney HEK-293 cells (Table 3). All the complexes are considerably 
more cytotoxic than RAPTA-C on the two cancer cell lines.  
Since both EA-CO2H and EA-(C=O)O(CH2)2OH might be generated from the ligands/complexes, their 
antiproliferative activities were also evaluated. The ester EA-(C=O)O(CH2)2OH shows a 15-20-fold 
higher cytotoxicity than the carboxylic acid EA-CO2H, most probably derived from the better uptake of 
the former into cells, due to increased solubility in the cell culture medium.10b Complex 1 has IC50 
values similar to those determined for EA-CO2H, whereas 2 - 4 are significantly more cytotoxic, albeit 
not too dissimilar from their corresponding ethacrynic acid-derived ligands LP and LN. Complex 3 is 
more cytotoxic than 4, both containing the same LN ligand, but the latter a PTA ligand in place of a 
chloride ligand. The IC50 values of 2 and 3 are comparable to those previously described for 
ruthenium(II)−arene complexes modified with an ethacrynic acid unit.10a,12,13 Nonetheless, 2 and 3 
display a slightly high selectivity towards cancer cells with respect to non-tumorigenic HEK-293 cells 
than the respective Ru-analogues (Table 3).13 
 
Table 3. IC50 values (μM) determined for RAPTA-C,25 ethacrynic acid (EA-CO2H),13 EA-(C=O)O(CH2)2OH, 
cisplatin, LP,13  LN13 and 1 - 4 on human ovarian (A2780 and A2780cisR) cancer cells and human embryonic 
kidney (HEK-293) cells after incubation for 72 h. Values are given as the mean ± SD. Values of the 
corresponding ruthenium analogues of 2 and 3 are given in parentheses.13 
 A2780 A2780cisR HEK-293 
RAPTA-C 230 270 >1000 
EA-CO2H 40 ± 3 53 ± 5 - 
EA-(C=O)O(CH2)2OH 2.0 ± 0.1 3.8 ± 0.7 3.3 ± 0.5 
LP 9 ± 1 40 ± 4 38 ± 9 
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LN 13 ± 2 11 ± 1 7 ± 1 
1 43 ± 6 69 ± 2 40 ± 4 
2 13 ± 2 
(11 ± 2) 
20 ± 5 
(15 ± 4) 
21 ± 2 
(13 ± 4) 
3 8 ± 1 
(13 ± 3) 
26 ± 8 
(26 ± 2) 
13 ± 1 
(16 ± 3) 
4 17 ± 3 34 ± 1 25 ± 2 
cisplatin 0.9 ± 0.1 25 ± 3 9 ± 2 
 
 
Intracellular GST inhibition 
Due to the potential of 1 - 4 to inhibit GSTs inside cells, residual intracellular GST activity after 
incubation with the complexes and the ligands at the respective IC50 concentrations was determined by 
fluorescence spectroscopy in A2780 and A2780cisR cells (Figure 4). Incubation for 18 hours led to a 
modest decrease in GST activity in both A2780 and A2780cisR cells with all the compounds, 1 being 
the least effective GST inhibitor. This appears to be in accordance with the low cytotoxicity exhibited 
by 1, which is prone to quickly release the ethacrynato anion in aqueous conditions (see above). 
In principle, both the EA-CO2H and EA-(C=O)O(CH2)2OH fragments might be generated inside the 
cells following dissociation of LN and LP from 2 - 4.15,26 The most pronounced effects on GST activity 
were observed for 2 (20% inhibition) and 4 (30% inhibition) in A2780 cells and to a lesser extent in 
A2780cisR cells, which indicates that the GSH/GST detoxification system in A2780cisR cells is more 
active, reflected by twofold higher IC50 values, compared to A2780 cells (Table 3). 
The ligand LN inhibits GST in A2780cisR cells slightly more than in A2780 cells, which might 
contribute to the comparable cytotoxicity in A2780 cells and A2780cisR cells, respectively (Table 3). 
The intracellular GST inhibition values of 2 - 4 do not correlate directly with the IC50 values (compare 
Table 3 and Figure 4), thus suggesting that the cytotoxicity of the compounds may only be partially 
attributed to GST inhibition. Indeed, these results are consistent with a previous mechanistic study on a 
bifunctional arene ruthenium(II)-ethacrynic acid compound, indicating that the EA-unit inhibits GSTs, 
releasing the organometallic fragment which leads to a surge of cell death.15a 
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Figure 4. Residual GST activity in A2780 and A2780cisR cells, expressed as % activity of control, after 
incubation at IC50 concentrations for 18 h. The changes in fluorescence over a 20 min period were used to 
calculate GST activities. 
 
Conclusions 
The first osmium complexes containing ethacrynic acid, a broad acting inhibitor of GSTs, have been 
synthesized and characterized. For two of the complexes, 2 and 3, ruthenium analogues are known, 
whereas 1 and 4 are unique in that no ruthenium congeners have been reported. Compounds 2 and 3 
are, as expected, more stable than the ruthenium analogues, in dmso/water and dmso/water/NaCl 
solutions. To within experimental error, there is no significant trend indicating that complexes of one 
metal (Ru or Os) are substantially more cytotoxic than the analogues of the other one, as previously 
noted.27 The complex with the most stable Os-EA ligand bond, i.e. 2, in which the ethacrynic acid 
entity is connected to the osmium(II) ion via a P-donor ligand, is not the most cytotoxic compound, 
indicating that dissociation of the bioactive EA group from the metal ion could be important in the 
mechanism of drug action. Indeed, the antiproliferative activity of 2 may be attributed predominantly to 
the ethacrynic acid-derived ligand, as their IC50 values are similar. This could explain why there is not 
a direct correlation between cytotoxicity and inhibition of intracellular GSTs, as the data suggest that 
GSTs are relevant targets, but not exclusive targets. Finally, incorporation of the pta ligand in 3 to 
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afford 4 does not improve the cytotoxicity or selectivity of the compounds, presumably due to the 
major role of the ethacrynic acid-derived ligand in the overall biological activity observed. 
 
Experimental 
OsCl3·3H2O (54% purity approx.) was purchased from Heraeus, while the organic reactants were 
purchased from Acros Organics and were of the highest purity available. Solvents were purchased from 
Scharlau and then obtained oxygen- and water-free with a MBraun solvent purification apparatus. The 
ligands PTA,17 LP 13 and LN 13 and the complexes [(η6-p-cymene)OsCl2]2,
28 Os(η6-p-cymene)(κ(C)-
acac)(κ(O,O')-acac) 16 and Os(η6-p-cymene)Cl2(PTA) 
18 were prepared according to the respective 
literature methods. NMR spectra were recorded on either a Bruker ARX 300 MHz or a Bruker Avance 
300 MHz instrument. Chemical shifts (expressed in parts per million) are referenced to the residual 
solvent peaks (1H, 13C{1H}) or to external standard (31P{1H} to 85% H3PO4). Coupling constants are 
given in Hz. Conductivity measurements were carried out using an Eutech Con 700 instrument (cell 
constant = 1.0 cm−1).29 UV-vis spectra were recorded with an Ultraspec 2100 Pro spectrophotometer. 
Attenuated total reflection infrared spectra (ATR-IR) of solid samples were recorded on a Perkin-Elmer 
Spectrum 100 FT-IR spectrometer. C, H, and N analyses were carried out with a Perkin-Elmer 2400 
CHNS/O analyzer. High-resolution electrospray mass spectra (HRMS) were acquired using a 
MicroTOF-Q hybrid quadrupole time-of-flight spectrometer (Bruker Daltonics, Bremen, Germany). 
 
Synthesis of Os(η
6
-p-cymene)(acetylacetonato)(2-(2,3-dichloro-4-(2-ethylenebutanoyl)phenoxy) 
acetato), 1 
A solution of Os(η6-p-cymene)(κ(C)-acac)(κ(O,O')-acac) (0.097 g, 0.19 mmol) in CH2Cl2 (5 mL) was 
treated with EA-CO2H (0.069 g, 0.23 mmol) and then left stirring at room temperature for 24 hours. 
The solvent was removed under vacuo to obtain a red oily residue. Repeated washings with Et2O (3 x 
10 mL) afforded 1 as a bright yellow powder. Yield 0.103 g, 75%. Crystals suitable for X-ray analysis 
were obtained by slow diffusion of pentane into a CH2Cl2 solution of 1. Anal. calcd. for 
C28H32Cl2O6Os: C, 46.34; H, 4.44. Found: C, 46.34; H, 4.28. ESI-MS(+): m/z found 749.106 [M+Na]
+, 
calcd. for C28H32Cl2NaO6Os
+ 749.108; the isotopic pattern fits well the calculated one. IR (solid state) 
υ: 2966w, 2936w, 2912w, 2876w, 1660m, 1644s, 1587m, 1575m, 1556m, 1518s, 1469m, 1434w, 
1383m, 1358vs, 1343w, 1285m, 1270m, 1265s, 1244w, 1219w, 1197w, 1146w, 1120w, 1083w, 1060s, 
1031w, 1006m, 962w, 938w, 925w, 891w, 864m, 823w, 803s, 785m, 757w, 729s, 684w, 659w, 633m, 
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610m cm-1. UV-Vis (CH2Cl2):  λmax/nm (ε/M−1cm−1) = 263 (7.4·103), 327 (1.9·103). ΛM (CH2Cl2) = 
0.12 S·cm2·mol–1. 1H NMR (CD2Cl2): δ = 7.01 (d, 1H, 
3JHH = 8.6 Hz, C11-H); 6.59 (d, 1H, 
3JHH = 8.6 
Hz, C10-H); 6.06, 5.82 (d, 4H, 3JHH = 5.6 Hz, arom CHcymene); 5.91, 5.58 (m, 2H, C4-H); 5.04 (s, 1H, 
CHacac); 4.55 (s, 2H, C12-H); 2.64 (sept, 1H, 
3JHH = 6.9 Hz, CHMe2); 2.43 (q, 2H, 
3JHH = 7.4 Hz, C2-
H); 2.17 (s, 3H, MeC6H4); 1.80 (s, 6H, Meacac); 1.24 (d, 6H, 
3JHH = 6.9 Hz, CHMe2); 1.12 ppm (t, 3H, 
3JHH = 7.4 Hz, C1-H). 
13C{1H} NMR (CD2Cl2): δ = 196.3 (C5); 185.8 (COacac); 172.5 (C13); 157.0 
(C9); 150.8 (C3); 132.5 (C8); 131.0 (C7); 128.3 (C4); 127.3 (C11); 122.3 (C6); 110.6 (C10); 99.2 
(CHacac); 88.6 (CCHMe2); 88.0 (CMecymene); 73.2, 68.5 (arom CHcymene); 67.7 (C12); 32.0 (CHMe2); 
27.0 (Meacac); 24.1 (C2); 22.9 (CHMe2); 18.4 (MeC6H4); 12.8 ppm (C1). 
Cl
Cl
O O
O
O
1
2 3
4
5 6 7 8
91011
12 13
Os
O
O
 
Chart 1. Os(η6-p-cymene)(κ(O,O')-acac)(κ(O)-O2C-EA), 1 (numbering refers to carbon atoms). 
 
Synthesis of Os(η
6
-p-cymene)Cl2(2-((4-(diphenylphosphanyl)benzyl)oxy)ethyl-2-(2,3-dichloro-4-
(2-methylenebutanoyl)phenoxy)acetato), 2 
Compound [Os(η6-p-cymene)Cl2]2 (0.137 g, 0.173 mmol) was added to a solution of LP (0.265 g, 
0.417 mmol) in CH2Cl2 (10 mL). The resulting orange solution was left stirring for 3 h at room 
temperature, then the volatile substances were removed under vacuo to afford an orange foamy residue. 
This solid was dissolved into a small volume of CH2Cl2 and loaded on top of a silica column (h 4.5 cm, 
d 2.5 cm). Impurities were eluted with CH2Cl2, then an orange band was eluted with CH2Cl2:THF 1:1 
v/v. Complex 2 was finally obtained as an orange powder after solvent removal under vacuo (50°C). 
Yield 0.319 g (90%). Anal. calcd. for C44H43Cl4O6OsP: C, 51.27; H, 4.20. Found: C, 51.08; H, 4.33. 
ESI-MS(+): m/z found 1053.097 [M+Na]+, calcd. for C44H43Cl4NaO6OsP
+ 1053.105; the isotopic 
pattern fits well the calculated one. IR (solid state) υ: 3058w, 2963w, 2957w, 1759m, 1720s, 1662m, 
1584m, 1568w, 1468m, 1435m, 1391w, 1384m, 1339w, 1263s, 1187s, 1111m, 1079vs, 1030m, 1017m, 
1000m, 948w, 895w, 858w, 800m, 762m, 749m, 721m, 696vs, 632w, 565w, 541s, 519vs cm-1. UV-Vis 
(CH2Cl2):  λmax/nm (ε/M−1cm−1) = 250 (2.3·104), 322 (1.9·103). ΛM (CH2Cl2) = 0.25 S·cm2·mol–1. 1H 
NMR (CD2Cl2): δ = 7.91-7.73, 7.44 (14H, C18-H + C18'-H + C19-H + C19'-H + Ph); 7.13 (d, 1H, 
3JHH 
= 8.5 Hz, C11-H), 6.84 (d, 1H, 3JHH = 8.5 Hz, C10-H); 5.95, 5.58 (m, 2H, C4-H); 5.43, 5.19 (d, 4H, 
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3JHH = 5.6 Hz, arom CHcymene); 4.80 (s, 2H, C12-H); 4.54 (s, 4H, C14-H + C15-H); 2.69 (sept, 1H, 
3JHH 
= 6.9 Hz, CHMe2); 2.45 (q, 2H, 
3JHH = 7.4 Hz, C2-H); 1.98 (s, 3H, MeC6H4); 1.17 (d, 6H, 
3JHH = 6.8 
Hz, CHMe2); 1.14 ppm (t, 3H, 
3JHH = 7.2 Hz, C1-H). 
13C{1H} NMR (CD2Cl2): δ = 196.3 (C5); 168.4 
(C13); 166.4 (C16); 156.1 (C9); 151.0 (C3); 140.7, 140.1 (m, C20 + P-C); 135.5-135.3 (m, C19 + C19' 
+ arom CHPh); 134.0 (C8); 133.4 (C7); 131.4 (C17); 131.3 (arom CHPh); 129.4 (C4); 129.2, 128.9 (m, 
C18 + C18' + arom CHPh); 127.7 (C11); 123.7 (C6); 111.7 (C10); 103.9 (CCHMe2); 90.0 (arom CMe); 
81.4 (d, 2JPC = 2.8 Hz, arom CHcymene); 81.1 (d, 
2JPC = 4.6 Hz, arom CHcymene); 66.9 (C12); 64.1, 63.3 
(C14 + C15); 31.0 (CHMe2); 24.2 (C2); 22.8 (CHMe2); 18.4 (MeC6H4); 13.0 ppm (C1). 
31P NMR 
(CD2Cl2): δ = −12.1 ppm. 
Cl
Cl
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Chart 2. Os(η6-p-cymene)Cl2(LP), 2 (numbering refers to carbon atoms). 
 
Synthesis of Os(η
6
-p-cymene)Cl2(2-(2-(2,3-dichloro-4-(2-methylenebutanoyl)phenoxy)acetoxy) 
ethyl nicotinato), 3 
This compound was prepared by the same procedure described for the synthesis of 2, from [(η6-p-
cymene)OsCl2]2 (0.100 g, 0.126 mmol) and LN (0.139 g, 0.307 mmol). Yellow solid, yield 0.153 g 
(75%). Crystals of 3·CH2Cl2·½[1,4-C6H4(OH)2] suitable for X-ray analysis were obtained by slow 
diffusion of hexane into a CH2Cl2 solution of 3, added of a few grains of hydroquinone. Anal. calcd. for 
C31H33Cl4NO6Os: C, 43.93; H, 3.92; N, 1.65. Found: C, 44.25; H, 4.10; N, 1.62. ESI-MS(+): m/z found 
812.096 [M-Cl]+, calcd. for C31H33Cl3NO6Os
+ 812.099; the isotopic pattern fits well the calculated one. 
IR (solid state) υ: 2964w, 2940w, 2893w, 1751m, 1728s, 1662m, 1584m, 1467w, 1432w, 1383w, 
1339w, 1286vs, 1194vs, 1137s, 1116s, 1079vs, 1062s, 1025m, 1000m, 941w, 891w, 876w, 820w, 
803m, 767w, 745s, 702w, 689m, 637w cm-1. UV-Vis (CH2Cl2):  λmax/nm (ε/M−1cm−1) = 259 (1.0·104), 
282 (6.8·103), 322 (4.3·103). ΛM (CH2Cl2) = 0.41 S·cm
2·mol–1. 1H NMR (CD2Cl2): δ = 9.51 (s, 1H, 
C18-H); 9.13 (m, 1H, C19-H); 8.29 (m, 1H, C21-H); 7.47 (m, 1H, C20-H); 7.18 (d, 1H, 3JHH = 8.6 Hz, 
C11-H); 6.95 (d, 1H, 3JHH = 8.6 Hz, C10-H); 5.99, 5.61 (m, 2H, C4-H); 5.86, 5.64 (d, 4H, 
3JHH = 5.7 
Hz, arom CHcymene); 4.94 (s, 2H, C12-H); 4.62 (s, 4H, C14 + C15); 2.80 (sept, 1H, 
3JHH = 6.9 Hz, 
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CHMe2); 2.47 (q, 2H, 
3JHH = 7.4 Hz, C2-H); 2.03 (s, 3H, MeC6H4); 1.31 (d, 6H, 
3JHH = 6.9 Hz, 
CHMe2); 1.16 ppm (t, 3H, 
3JHH = 7.4 Hz, C1-H). 
13C{1H} NMR (CD2Cl2): δ = 196.0 (C5); 168.3 (C13); 
163.7 (C16); 158.1 (C19); 155.9 (C18); 155.8 (C9); 150.7 (C3); 139.1 (C21); 134.3 (C8); 131.6 (C7); 
129.1 (C4); 127.6 (C11); 127.4 (C17); 125.0  (C20); 123.3 (C6); 111.5 (C10); 94.1 (CCHMe2); 89.4 
(arom CMe); 75.9, 73.4 (arom CHcymene); 66.6 (C12); 63.9, 63.3 (C14, C15); 31.5 (CHMe2); 23.9 (C2); 
22.8 (CHMe2); 18.4 (MeC6H4); 12.8 ppm (C1).  
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Chart 3. (η6-p-cymene)OsCl2(LN), 3 (numbering refers to carbon atoms). 
 
Synthesis of Os(η
6
-p-cymene)Cl(2-(2-(2,3-dichloro-4-(2-methylenebutanoyl)phenoxy)acetoxy) 
ethylnicotinato)(1,3,5-triaza-7-phosphaadamantane) tetrafluoroborato, 4 
A stirred solution of Os(η6-p-cymene)Cl2(PTA) (0.100 g, 0.181 mmol) in CH2Cl2 (6 mL) was treated 
with LN (0.098 g, 0.216 mmol) and then with AgBF4 (0.048 g, 0.25 mmol). The mixture was stirred 
for 72 h at room temperature under protection from the light. The final mixture was filtered through 
Celite, then the volatiles substances were removed under vacuo. The residue was precipitated with Et2O 
(30 mL) and then washed with hexane (20 mL). Complex 4 was obtained as a pale-yellow solid. Yield 
0.156 g (81%). Anal. calcd. for C37H45BCl3F4N4O6OsP: C, 42.08; H, 4.29; N, 5.30. Found: C, 42.70; H, 
4.36; N, 5.47. ESI-MS(+): m/z found 969.177 [M]+, calcd. for C37H45Cl3N4O6OsP
+ 969.175; the 
isotopic pattern fits well the calculated one. IR (solid state) υ: 2967w, 2936w, 2880w, 1757m-sh, 
1733s, 1662m, 1585m, 1469m, 1444w-m, 1385w-m, 1288s, 1242m, 1197s, 1138m, 1117s-sh, 1054vs-
br, 973s, 947s, 896m, 803m, 766w-m, 744s, 695w-m, 606w, 577s cm-1. UV-Vis (CH2Cl2):  λmax/nm 
(ε/M−1cm−1) = 258 (1.4·104), 317 (5.2·103). ΛM (CH2Cl2) = 9.32 S·cm
2·mol–1. 1H NMR (CD2Cl2): δ = 
9.55 (s, 1H, C18-H); 9.09 (d, 1H, 3JHH = 5.5 Hz, C19-H); 8.43 (d, 1H, 
3JHH = 8.0 Hz, C21-H); 7.74 (m, 
1H, C20-H); 7.15 (d, 1H, 3JHH = 8.6 Hz, C11-H); 6.89 (d, 1H, 
3JHH = 8.6 Hz, C10-H); 6.03, 5.79 (d, 4H, 
3JHH = 5.7 Hz, arom CHcymene); 5.96, 5.58 (m, 2H, C4-H); 4.88 (d, 2H, 
2JHH = 1.5 Hz C12-H); 4.71-4.58 
(m, 6H, NCH2N); 4.62 (s, 4H, C14 + C15); 4.19 (q, 6H, 
2JHP = 15.4 Hz, NCH2P); 2.54 (sept, 1H, 
3JHH = 
6.6 Hz, CHMe2); 2.44 (q, 2H, 
3JHH = 7.3 Hz, C2-H); 2.05 (s, 3H, MeC6H4); 1.26 (d, 6H, 
3JHH = 6.8 Hz, 
CHMe2); 1.13 ppm (t, 3H, 
3JHH = 7.4 Hz, C1-H). 
13C{1H} NMR (CD2Cl2): δ = 196.1 (C5); 168.4 (C13); 
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163.2 (C16); 161.2 (C19); 156.7 (C18); 155.9 (C9); 150.8 (C3); 140.8 (C21); 134.6 (C8); 131.8 (C7); 
129.2 (C4); 129.0 (C17); 127.6 (C11); 127.6 (C20); 123.3 (C6); 111.7 (C10); 104.3 (CCHMe2); 95.0 
(arom CMe); 75.9, 73.4 (arom CHcymene); 72.9 (NCH2N); 66.8 (C12); 64.5, 63.5 (C14, C15); 49.5 (d, 
1JCP = 21.1 Hz, NCH2P); 31.6 (CHMe2); 24.0 (C2); 23.0, 22.4 (CHMe2); 18.4 (MeC6H4); 12.8 ppm 
(C1). 31P NMR (CD2Cl2): δ = −77.4 ppm. 
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Chart 4. [(η6-p-cymene)OsCl(LN)(PTA)][BF4], 4 (numbering refers to carbon atoms). 
 
Synthesis of EA-CO2K. KN(SiMe3)2 (0.36 mL, 0.33 mmol) was added to a solution of EA-CO2H 
(0.100 g, 0.330 mmol) in Et2O (10 mL), under nitrogen atmosphere. The mixture was left stirring for 
additional 24 h. The resulting colorless solid was separated, washed with pentane (20 mL) and dried 
under vacuo. Yield 0.075 g, 66.6%. Anal. calcd. for C13H11Cl2KO4: C, 45.76; H, 3.25; Cl, 20.78. 
Found: C, 45.71; H, 3.18; Cl, 20.82. IR (solid state): ν = 2965w, 2938w, 2922w, 2878w, 2550w, 
1657m (C=O), 1598vs (COO), 1586vs, 1554m, 1471m-s, 1417s, 1385m, 1339m, 1267m-s, 1202m, 
1120w, 1054vs, 1002m, 941m, 908w, 824w, 799s, 760m, 737m, 724m, 698w, 680w, 627m, 590w, 
570w, 531w cm−1. 1H NMR (D2O): δ = 7.26 (d, 
3JHH = 8.80 Hz, 1H, C10-H); 6.92 (d, 
3JHH  = 8.80 Hz, 
1H, C11-H); 6.08, 5.69 (s, 2 H, C4-H); 4.58 (s, 2 H, C12-H); 2.36 (m, 2 H, C2-H); 1.06 (m, 3 H, C1-H) 
ppm. 13C NMR (D2O): δ = 199.2 (C5); 174.9 (C13); 156.1 (C9); 150.1 (C6); 131.8 (C7), 131.6  (C8);  
130.3  (C3);  128.0  (C11);  122.0  (C4);  111.1  (C10);  67.8  (C12);  23.2 (C2); 12.0 (C1) ppm. 
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Chart 5. EA-CO2K (numbering refers to carbon atoms). 
 
Stability studies 
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General procedure. Complexes 1−4 were dissolved in the selected d6-dmso/D2O mixture (2.0 mL) 
([Os] = 2.1·10-2 mol L-1). An aliquot of the resulting solution (0.40 mL) was transferred into a NMR 
tube, maintained at 37 °C and analyzed by NMR spectroscopy as a function of time. The remaining 
solution was diluted up to 4.2 mL with the appropriate dmso/water mixture (final [Os] = 7.8·10-3 mol L-
1), maintained at 37 °C and analyzed by conductivity measurements and UV-Vis spectroscopy as a 
function of time (t). Parallel analyses were carried out on dmso/water mixtures prepared by the same 
procedure described above, and with the addition of NaCl (ca. 0.1 M). CH3OD (2.5·10
-2 mol L-1) was 
used as a reference for the 1H NMR spectra. For NMR assignments refer to Scheme 3. The NMR 
spectra of LP, LN, EA-CO2H, EA-C(=O)O(CH2)2OH, PTA and acacH were recorded in d
6-dmso/D2O 
(9:1 v/v) and used for comparison for NMR assignments. FeCp2 was selected as an organometallic 
standard for conductivity data (ΛM = 0.69 S·cm
2·mol–1 in dmso/H2O 9:1 at 37 °C). 
Compound 1. ΛM (dmso/water 9:1) = 3.4 S·cm
2·mol–1 (t = 5 min); 5.3 S·cm2·mol–1 (t = 50 min); 4.6 
S·cm2·mol–1 (t = 6 h); 5.3 S·cm2·mol–1 (t = 24 h); 3.8 S·cm2·mol–1 (t = 114 h). UV-Vis (dmso/water 9:1), 
λmax/nm (ε/M−1cm−1) = 327 (2.6·103) (t = 2 h - 114 h). UV-Vis (dmso/water 9:1 + NaCl 0.1 M) = 330 
(2.7·103) (t = 2 h); 330 (2.1·103) (t = 72 h). 1H NMR (d6-dmso/D2O 9:1): δ = 7.23 (d, EACO2
−), 7.16 
(d, 1), 6.91 (d, EACO2
−), 6.67 (d, 1), 6.24 (s, 1a), 6.13 (s, 1a), 6.03 (s, 1 + EACO2
−), 5.86 (s, 1a), 5.55 
(s, EACO2
−), 5.54 (s, 1), 4.97 (s, 1), 4.52 (s, 1), 4.47 (s, EACO2
−), 2.33 (q, 1 + EACO2
−), 1.95 (s, 1), 
1.69 (s, 1 + 1a), 1.20 (d, 1), 1.14 (d, 1a), 1.04 (t, 1 + EACO2
−). Ratio 1 : EACO2
−
 : 1a = 1:1:1 (t = 1 - 
72 h). 1H NMR (d6-dmso/D2O 9:1 + NaCl 0.1 M): 1, EACO2
− and 1b [δ = 6.00 (d), 5.78 (d), 5.31 (s), 
2.08 (s), 1.80 ppm (s)], ratio 2:8:7 (t = 5 min), 0:5:3 (t = 2 - 72 h). 
Compound 2. ΛM (dmso/water 9:1) = 8.9 S·cm
2·mol–1 (t = 5 min - 72 h). UV-Vis (dmso/water 9:1), 
λmax/nm (ε/M−1cm−1) = 322 (2.8·103), 423 (4.3·102) (t = 5 min - 72 h). UV-Vis (dmso/water 9:1 + NaCl 
0.1 M) = 320 (2.8·103), 423 (4.0·102) (t = 5 min); 320 (2.4·103), 423 (4.0·102) (t = 72 h). 1H NMR (d6-
dmso/D2O 9:1 or d6-dmso/D2O 9:1 + NaCl 0.1 M): δ = 7.85 (m, 2H), 7.79 (m, 2H), 7.64 (m, 4H), 7.43 
(m, 6H), 7.18, 7.11 (d, 2H), 6.00 (s, 1H), 5.50, 5.37 (d, 4H), 5.47 (s, 1H), 5.01 (s, 2H), 4.45 (s, 4H), 
2.41 (m, 1H), 2.31 (q, 2H), 1.83 (s, 3H), 1.02 (t, 3H), 0.98 ppm (d, 6H) (t = 5 min - 72 h). 13C{1H} 
NMR (d6-dmso/D2O 9:1 or d6-dmso/D2O 9:1 + NaCl 0.1 M): δ = 195.7, 168.4, 165.7, 155.5, 149.7, 
134.8-134.5, 133.3, 133.0, 132.9, 131.1, 130.1, 128.6-128.4, 127.8, 112.1, 88.9, 81.3, 80.3, 66.0, 63.4, 
63.2, 30.1, 23.3, 22.1, 17.5, 12.7 ppm (t = 5 min - 72 h). 31P NMR (d6-dmso/D2O 9:1): δ = −12.8 ppm 
(t = 5 min - 22 h); δ = −12.8 (major, 2a), 26.6 (ca. 6%, LP=O) ppm (t = 51 h - 72 h). 31P NMR (d6-
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dmso/D2O 9:1 + NaCl 0.1 M): δ = −12.8 (major, 2a), 26.6 (ca. 9%, LP=O) ppm (t = 5 min - 23 h); 
−12.8 (major, 2a), −6.3 (LP, ca. 7%), 26.6 (ca. 5%, LP=O) ppm (t = 72 h). 
Compound 3. ΛM (dmso/water 9:1) = 2.2 S·cm
2·mol–1 (t = 5 min); 3.2 S·cm2·mol–1 (t = 50 min); 3.4 
S·cm2·mol–1 (t = 6 h); 3.3 S·cm2·mol–1 (t = 24 h); 3.9 S·cm2·mol–1 (t = 114 h). UV-Vis (dmso/water 9:1), 
λmax/nm (ε/M−1cm−1) = 322 (2.2·103), 418 (3.6·102) (t = 5 min - 72 h). UV-Vis (dmso/water 7:3 + NaCl 
0.1 M) = 322 (1.6·103), 418 (2.4·102) (t = 5 min); 322 (1.8·103), 418 (2.4·102) (t = 72 h). 1H NMR (d6-
dmso/D2O 9:1): δ = 9.30 (s, 3 + 3a), 9.04 (s, LN), 8.99 (t, 3a), 8.98 (d, 3), 8.78 (d, LN), 8.47 (d, 3a), 
8.30 (d, 3), 8.24 (d, LN), 7.77 (m, 3a), 7.59 (dd, 3), 7.54 (dd, LN), 7.23 (d, 3 + 3a), 7.16 (d, LN), 7.14 
(m, 3a), 7.10 (d, LN), 6.38 (d, 3a), 6.25 (d, 3a), 6.17 (d, 3a), 6.08 (d, 3a), 6.04 (d, 3b), 6.03 (s, LN), 
5.94 (d, 3b), 5.92 (d, 3), 5.74 (d, 3), 5.52 (s, 3a), 5.49 (s, LN), 5.04 (s, LN), 4.50 (s, LN), 2.70 (m, 3b), 
2.33 (q, LN), 2.14 (s, 3a), 2.11 (s, 3b), 1.89 (s, 3), 1.17 (d, 3b), 1.04 ppm (t, LN). Ratio 3 : 3a : 3b : 
LN = 13:0:87:88 (t = 5 min), 10:7:79:82 (t = 1 h), 10:5:83:87 (t = 3 h), 11:6:82:77 (t = 48 h), 
11:6:83:81 (t = 114 h). 1H NMR (d6-dmso/D2O 7:3 + NaCl 0.1 M): 3, 3a, 3b and LN, ratio 25:10:70:60 
(t = 5 min - 72 h). 13C{1H} NMR (d6-dmso/D2O 9:1): δ = 195.7 (LN), 168.4 (LN), 165.1 (LN), 155.5 
(LN), 154.1 (LN), 150.4 (LN), 149.7 (LN), 137.5 (LN), 133.0 (LN), 130.1 (LN), 127.8 (LN), 125.8 
(LN), 124.4 (LN), 121.5 (LN), 112.0 (LN), 98.4 (3b), 93.6 (3b), 78.5 (3b), 78.4 (3b), 65.9 (LN), 63.5 
(LN), 63.1 (LN), 30.3 (3b), 23.3 (LN), ): 22.1 (3b), 18.1 (3b), 12.7 ppm (LN) (t = 72 h). 
Compound 4. ΛM (dmso/water 9:1) = 67 S·cm
2·mol–1 (t = 5 min); 60 S·cm2·mol–1 (t = 2 h); 65 
S·cm2·mol–1 (t = 24 h); 71 S·cm2·mol–1 (t = 62 h). UV-Vis (dmso/water 9:1), λmax/nm (ε/M−1cm−1) = 
317 (8.2·103) (t = 5 min); 317 (4.1·103) (t = 62 h). UV-Vis (dmso/water 1:1 + NaCl 0.1 M) = 317 
(8.3·103) (t = 5 min); 317 (6.9·103) (t = 62 h). 1H NMR (d6-dmso/D2O 9:1): δ = 9.31 (s, 4a), 9.04 (m, 
LN), 8.92 (d, 4a), 8.75 (m, LN), 8.41 (d, 4a), 8.24 (m, LN), 7.62 (m, 4a), 7.54 (m, LN), 7.24 (d, 4a), 
7.16 (d, LN), 7.11 (d, 4a), 7.09 (d, LN), 6.57 (d, 4b), 6.39 (d, 4b), 6.27 (d, 4b), 6.15 (m, 4a), 6.07 (d, 
4b), 6.06 (m, 4a), 6.03 (s, LN), 5.96 (d, 4a), 5.51 (s, 4a), 5.48 (s, LN), 5.02 (s, 4a), 4.50 (m-br, 4a + 
LN), 4.26 (q, 4b), 4.06 (q, 4a), 2.43 (m, 4a), 2.33 (q, 4a), 2.25 (s, 4b), 1.93 (s, 4a), 1.15 (d, 4a), 1.04 (t, 
4a). Ratio 4a : 4b : LN = 100:0:0 (t = 5 min), 45:50:55 (t = 24 h), 23:60:63 (t = 46 h), 17:65:67 (t = 62 
h). 1H NMR (d6-dmso/D2O 1:1 + NaCl 0.1 M): 4a, 4b, and 4c [δ = 8.92 (m), 8.64 (d), 8.21 (d), 7.49 
(m), 7.01 (d), 6.92 (d), 6.97, 6.02, 5.98, 5.90, 5.41 (s), 4.91 (s), 2.01 ppm (s)]. Ratio 100:0:0 (t = 5 
min), 100:31:11 (t = 24 h), 100:70:20 (t = 46 h), 100:100:20 (t = 62 h). LN is not soluble in these 
conditions. 13C{1H} NMR (d6-dmso/D2O 9:1): δ = LN and 4a [δ = 86.6, 83.8, 71.8, 51.3, 30.8, 22.2, 
22.0, 18.6 ppm] (t = 62 h). 31P NMR (d6-dmso/D2O 9:1): δ = −76.5 (4a), −74.8 (4b) ppm. Ratio 100:0 
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(t = 2 h), 42:58 (t = 24 h), 23:76 (t = 46 h), 17:82 (t = 62 h). 31P NMR (d6-dmso/D2O 1:1 + NaCl 0.1 
M): 4a, 4b, and 4c [δ = −72.0 ppm]. Ratio 100:0:0 (t = 2 h), 64:35:0 (t = 24 h), 46:46:7 (t = 46 h), 
35:47:12 (t = 62 h). 
 
X-ray crystallography 
Crystal data and collection details for 1 and 3·CH2Cl2·½[1,4-C6H4(OH)2] are reported in Table 4. X-ray 
data were collected on Bruker Smart APEX CCD (3) and Smart Apex CCD DUO (1) diffractometers 
equipped with a normal focus, 2.4 kW sealed tube source (Molybdenum radiation, λ = 0.71073 Å), 
operating at 50 kV and 30 (1) or 40 (3) mA. Data were collected over the complete sphere by a 
combination of four sets. Each frame exposure time was 30 s (1) or 10 s (3), covering 0.3o in ω. Data 
were corrected for absorption by using a multiscan method applied with the Sadabs program.30 The 
structures were solved by the Patterson method or by direct methods. Refinement, by full-matrix least 
squares on F2 with SHELXL97,31 was similar for the two complexes, including isotropic and 
subsequently anisotropic displacement parameters. The hydrogen atoms were observed or calculated 
and refined freely, or using a restricted riding model. In the case of 3, half molecule of hydroquinone 
(added to facilitate the crystallization, vide infra) and one molecule of dichloromethane were observed 
in the asymmetric unit. All the highest electronic residuals were observed in the close proximity of the 
Os centers and do not hold any chemical significance. 
 
Table 4. Crystal data and measurement details for 1 and 3·CH2Cl2·½[1,4-C6H4(OH)2]. 
Complex 1 3·CH2Cl2·½[1,4-C6H4(OH)2] 
Formula C28H32Cl2O6Os C35H38Cl6NO7Os 
FW 725.64 987.56 
T, K
 
100(2) 100(2) 
λ,  Å 0.71073 0.71073 
Crystal system orthorhombic monoclinic 
Space group Pbca P21/n 
a, Å 19.6723(19) 17.0370(17) 
b, Å 11.5289(11) 13.3798(13) 
c, Å 24.095(2) 17.2905(17) 
β, ° 
 103.3800(10) 
Cell Volume, Å3 5464.8(9) 3834.4(7) 
Z 8 4 
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Dc, g·cm-3 1.764 1.711 
µ, mm−1 4.903 3.791 
F(000) 2864 1956 
Crystal size, mm 0.10 x 0.09 x 0.06 0.19 x 0.10 x 0.06 
θ limits, ° 1.7 – 29.6 1.9 – 28.6 
Reflections collected 57473 45640 
Independent reflections 7332 9208 
Data / restraints /parameters 7332 / 0 / 340 9208 / 4 / 457 
Goodness of fit on F2 1.011 1.001 
R1 (I > 2σ(I)) 0.0299 0.0389 
wR2 (all data) 0.0621 0.0821 
Largest diff. peak and hole, e Å-3 1.501, -1.111  1.146, -1.313 
 
Cell culture 
Human A2780 and A2780cisR ovarian carcinoma cells were obtained from the European Centre of 
Cell Cultures (ECACC, UK). Nontumorigenic HEK-293 cells were obtained from ATCC (Sigma, 
Switzerland). A2780 and A2780cisR were routinely grown in RPMI 1640 GlutaMAX 
(Lifetechnologies, Switzerland), while HEK-293 were grown in DMEM medium, both containing 10% 
heat-inactivated fetal bovine serum (FBS, Pan Biotech, Germany) and 1% antibiotics 
(penicillin/streptomycin), at 37 °C and CO2 (5%). 
 
Determination of antiproliferative activity  
Cytotoxicity was determined using the MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide). Cells were seeded in 96-well plates as monolayers with 100 µL of cell 
solution per well and pre-incubated for 24 h in the cell culture medium. Compounds were prepared as 
DMSO solutions that were rapidly dissolved in the culture medium and serially diluted to the 
appropriate concentration to give a final DMSO concentration of 0.5%. 100 µL of the drug solution 
were added to each well and the plates were incubated for another 72 h. Subsequently, MTT (5 mg/mL 
solution) was added to the cells and the plates were incubated for further 4 h. The culture medium was 
aspirated, and the purple formazan crystals formed by the mitochondrial dehydrogenase activity of vital 
cells were dissolved in DMSO. The optical density, directly proportional to the number of surviving 
cells, was quantified at 590 nm using a multiwell plate reader (Molecular Devices) and the fraction of 
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surviving cells was calculated from the absorbance of untreated control cells. Evaluation is based on 
means from three independent experiments, each comprising four testings per concentration level. 
 
GST activity assay 
A2780 and A2780cisR cells were plated in six well plates (2x106 cells/well) and incubated for 24 h in a 
CO2 incubator at 37 °C. The cells were then exposed to compounds LN, LP, EA-(C=O)O(CH2)2OH, 
1–4 for 18 h, at final concentrations according to the IC50 concentration for each respective cell line. 
The cells were then washed twice with PBS, harvested, lysed by a repetitive freeze–thaw cycle, and 
centrifuged at 10 000g for 15 min at 4 °C. The supernatants were used for the analysis of GST activity 
according to a fluorometric GST detection kit (Abnova). The changes in fluorescent intensities at 
Ex/Em 380/460 nm were recorded in a kinetic mode, every 5 min over 60 min, on a microplate reader 
(Molecular Devices). Two independent experiments were performed in which the GST activities were 
measured in duplicate. The GST activity expressed as U/min/mL per mg protein was converted to % 
activity of control (non-treated cells). The GST activity of the test samples was calculated by applying 
the equation ∆RFU = RFU2 – RFU1 to the GST standard curve to get B [mU] during the reaction time 
(∆T = T2 – T1). The sample GST activity is calculated by the following formula: sample GST activity = 
B/(∆T × V) × dilution factor [mU/min/mL], where B is sample GST activity from the GST standard 
curve [mU], ∆T is the reaction time (min), V is the sample volume added into the reaction well [mL]. 
 
Protein Determination 
The protein concentration was determined by a Bradford assay (Bio-Rad) using BSA as a standard. 
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